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Background: ACCEPt, a large cluster randomized control trial, aims to determine if annual testing for 16 to 29 year
olds in general practice can reduce chlamydia prevalence. ACCEPt is the first trial investigating the potential role of
practice nurses (PN) in chlamydia testing. To inform the design of the ACCEPt intervention, we aimed to determine
the chlamydia knowledge, attitudes, and testing practices of participating general practitioners (GPs) and PNs.
Methods: GPs and PNs from 143 clinics recruited from 52 areas in 4 Australian states were asked to complete a
survey at time of recruitment. Responses of PNs and GPs were compared using conditional logistic regression to
account for possible intra cluster correlation within clinics.
Results: Of the PNs and GPs enrolled in ACCEPt, 81% and 72% completed the questionnaire respectively. Less than
a third of PNs (23%) and GPs (32%) correctly identified the two age groups with highest infection rates in women
and only 16% vs 17% the correct age groups in men. More PNs than GPs would offer testing opportunistically to
asymptomatic patients aged ≤25 years; women having a pap smear (84% vs 55%, P<0.01); antenatal checkup (83%
vs 44%, P<0.01) and Aboriginal men with a sore throat (79% vs 33%, P<0.01), but also to patients outside of the
guideline age group at the time of the survey; 26 year old males presenting for a medical check (78% vs 30%,
P = <0.01) and 33 year old females presenting for a pill prescription (83% vs 55%, P<0.01). More PNs than GPs knew
that retesting was recommended after chlamydia treatment (93% vs 87%, P=0.027); and the recommended
timeframe was 3 months (66% vs 26%, P<0.01). A high proportion of PNs (90%) agreed that they could conduct
chlamydia testing in general practice, with 79% wanting greater involvement and 89% further training.
Conclusions: Our survey reveals gaps in chlamydia knowledge and management among GPs and PNs that may be
contributing to low testing rates in general practice. The ACCEPt intervention is well targeted to address these and
support clinicians in increasing testing rates. PNs could have a role in increasing chlamydia testing.* Correspondence: rlorch@kirby.unsw.edu.au
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Chlamydia trachomatis (hereafter referred to as chla-
mydia) is the most common reportable infection in the
United States (US), Europe and Australia. In 2011,
around 1.4 million new chlamydia diagnoses were re-
ported in the US, 344 491 in 24 European Union mem-
ber states during 2010 and 80 800 in Australia in 2011
[1-3]. In these countries, notifications of chlamydia are
increasing steadily each year, with most cases in 15-29 year
olds [1-3]. Without treatment, chlamydia may persist for a
year or longer, with an estimated 10% of young women
developing pelvic inflammatory disease within a year [4,5].
Untreated chlamydia is also an important cause of other
serious reproductive morbidity including infertility and
ectopic pregnancy [6,7].
Most chlamydia infections are asymptomatic [7], and
in the absence of screening they may remain undetected.
Clinical guidelines in various countries recommend regu-
lar testing of sexually active women aged less than 25 years,
with England extending the recommendation to include
males, and Australia recently extending to males and up
to age 29 years [8-10]. Australian general practice clinics
are ideally placed to conduct widespread chlamydia
screening with 86% of women and 64% of men aged 16-
29 years of age visiting a general practitioner (GP) at least
once each year; however testing rates in this age group are
low at 12.1% in women and 4.8% in men [11].
The Australian Government has funded the Australian
Chlamydia Control Effectiveness Pilot (ACCEPt), a cluster
randomised controlled trial of annual chlamydia testing in
16-29 year old males and females. ACCEPt aims to deter-
mine whether annual chlamydia screening in general prac-
tice can reduce the prevalence of chlamydia. Clinics are
randomised to either receive a multifaceted intervention
designed to facilitate increased testing or to continue
with usual care. Further details about the intervention
are described elsewhere [12]. Given the growth of the
role of the practice nurse (PNs) (employed in around
60% of Australia’s general practices) in recent years,
there is an opportunity for PNs to take a role in chlamydia
testing [13,14]. ACCEPt clinics randomised to the inter-
vention arm can choose for PNs to become more involved
in testing and management and receive PN specific edu-
cation and financial incentives. Although PNs have been
recognized as having the potential to play a key role in
the provision of sexual health services in general prac-
tice in the UK [15,16] to our knowledge, ACCEPt is also
the first chlamydia screening trial to formally evaluate
the impact of practice nurses in increasing chlamydia
testing rates.
To inform the design of the ACCEPt intervention in
supporting GPs and PNs to increase testing rates and to
assess the scope for PN involvement in chlamydia test-
ing in clinics, we aimed to determine the chlamydiaknowledge, attitudes, awareness and testing practices of
participating GPs and PNs prior to randomization and
education. Although other surveys have been conducted
among GPs in Australia [17-21], none have included
PNs. We also assessed if PNs demonstrated any differ-
ences in these outcomes compared with GPs which
could require tailoring of the intervention.Methods
Setting
In Australia, there are 7 093 general practice clinics [22].
Patients can be registered at multiple clinics and are able
to consult with multiple doctors. The majority of the pa-
tient’s costs for a GP consultation are covered by Medicare
Australia, the universal medical insurance scheme [23].
Clinics receive most of their income by fee per service,
with ~85% directly billed to the Australian government
through the Medicare rebate system. Income is also gener-
ated through patient fees charged in addition to the Medi-
care rebate and a small proportion through government
incentive payments for activities aimed at encouraging
general practices to improve patient health outcomes and
quality of care [24]. In the past, GP clinics were also able
to receive rebates for PNs involvement in a select range of
duties such as wound dressings, immunisations and cer-
vical screening and thus their work often focused on these
income generating areas [25]. Recent restructuring of PN
funding arrangements into a single funding stream, aiming
to support an enhanced role for PNs, now allows them to
undertake a broader range of activities in areas including
preventative health [13].
There are 143 general practice clinics participating in
ACCEPt, based in 52 rural areas (postcodes) of New
South Wales, Victoria, Queensland and South Australia.
Areas were classified as rural according to 2006 Australian
Bureau of Statistics census data [26]. ACCEPt towns were
selected from geographical areas within Divisions of
General Practice with a minimum population size of
500 16 to 29 year olds. All clinics in the towns were eli-
gible for participation if they were a general practice. If
one or more clinics in the area declined to participate,
then the area was considered ineligible for participation.
An additional 9 clinics in metropolitan areas partici-
pated and were eligible if they saw a minimum of 200
patients aged 16 to 29 years each month. These metro-
politan clinics were recruited to assess feasibility and
did not formally participate in the trial.Study design
A cross sectional survey examining chlamydia know-
ledge, awareness and testing practices was conducted
among PNs and GPs participating in ACCEPt.
Lorch et al. BMC Family Practice 2013, 14:169 Page 3 of 10
http://www.biomedcentral.com/1471-2296/14/169Participants
All PNs and GPs who had provided consent to partici-
pate in ACCEPt were invited to complete the survey at
time of clinic recruitment, prior to randomisation of
that clinic to either the control or intervention arm of
the trial and before any education was undertaken.
Overall, 90% of clinics approached agreed to participate
in ACCEPt and 75% of GPs from participating clinics
were recruited. PNs were recruited if the clinic practice
manager or principal GP thought they may have a role
in chlamydia testing.Questionnaire administration and reminders
Participants were encouraged to complete the survey
immediately after completing the ACCEPt consent docu-
mentation at the initial clinic recruitment meeting, and
hand it back to research staff. Participants who were un-
able to complete the form at the clinic recruitment meet-
ing were provided with reply paid envelopes in which to
return surveys. Non-responders were reminded via the
practice manager of the clinic, or though a letter sent by
the researchers.Questionnaire content
A self administered, paper questionnaire was used. There
were separate questionnaires for GPs and PNs. Both
questionnaires captured clinician demographics, clinical
experience, training, chlamydia knowledge and testing
and management practices. A number of case vignettes
that described a range of patient presentations were in-
cluded and respondents indicated whether chlamydia
testing should be offered and the correct specimens to
be collected. The GP survey included additional questions
about chlamydia treatment and the complications of chla-
mydia, and the PN survey had additional questions about
opinions regarding chlamydia testing and perceived bar-
riers to increasing chlamydia testing. Responses were
mostly Likert scales with scores of 1 to 5. The GP survey
was designed first and used as a basis for the PN survey,
with questions removed, modified or added to reflect the
PNs scope of practice and the variability of PN roles. We
conducted pilot testing with both GPs and PNs, to ensure
validity with the target group and feasibility of question-
naire length.
Correct answers for the knowledge and practice
questions were based on data from the National Noti-
fiable Diseases Surveillance System, information from
the Royal Australian College of General Practitioners
(RACGP) Guidelines for Preventive Activities in General
Practice, current at the time of the survey and The
National Management Guidelines for Sexually Trans-
missible Infections [9,27].Data analysis
Conditional logistic regression was used to explore the
differences in the responses between PNs and GPs and
to account for any possible intra cluster correlation
within clinics. Odds ratios (OR) and confidence intervals
(CI) were obtained, and p-values of <0.05 were consid-
ered statistically significant. Descriptive statistics were
used to examine the responses of GPs to questions about
chlamydia treatment and the responses of PN to the
questions about opinions regarding chlamydia testing
and perceived barriers to increasing chlamydia testing.
Analysis was carried out using Stata 12.0 (College Station,
TX).
Ethical approval
The ACCEPt trial received ethical approval from the Royal
Australian College of General Practitioners National Re-
search and Evaluation Ethics Committee, the Aboriginal
Health and Medical Research Council Ethics Committee




At the time of the survey 146 PNs and 773 GPs were
enrolled in ACCEPt, with 118 (81%) and 556 (72%)
returning the survey, respectively. Most of the PN par-
ticipants (98%) were female, compared with 39% of GP
participants. The majority of the participants were aged
between 30-59 years (84%); a slightly higher proportion of
PNs were aged 45-59 years (51% vs 46%) compared with
GPs but the difference was not significant.
The majority of participants (84%) had been qualified
for longer than ten years, but PNs had worked in the
field of general practice for less time than GPs. PNs were
more likely than GPs to have undertaken their primary
training in Australia rather than overseas (93% vs 59%)
and more likely than GPs to have a special interest in
sexual health (47% vs 29%) (see Table 1). At the time of
the survey, under half of the PNs (41%) reported involve-
ment in chlamydia testing, whilst most GPs (81%) indi-
cated that they were performing between 1 - 10 chlamydia
tests per month.
Chlamydia knowledge
Less than a third of PNs and GPs could correctly identify
both age groups (16-19, and 20-24 years) with the highest
rates of chlamydia in women (23% vs 32%), and an even
lower proportion correctly identified both age groups (20-
24 and 25-29 years) in men (16% vs 17%) with no signifi-
cant differences between PNs and GPs. The majority of
PNs and GPs correctly agreed with the statement that
“most chlamydia infections are asymptomatic” in women
(88% vs 90%) with a slightly lower proportion agreeing
Table 1 Characteristics and chlamydia knowledge of participants
Characteristic Overall n (%) GP n (%) PN n (%) OR (95% CI) P value
Sex
Male 340 (50.4) 338 (60.8) 2 (1.7) Ref
Female 334 (49.6) 218 (39.2) 116 (98.3) 110.8 (15.2, 806.6) <0.01
Age group
<30 years 42 (6.2) 35 (6.3) 7 (5.9) Ref
30-44 years 54 (37.7) 215 (38.7) 39 (33.1) 0.9 (0.3, 2.8) 0.96
45-59 years 313 (46.4) 253 (45.5) 60 (50.9) 1.6 (0.5, 4.5) 0.36
>60 years 65 (10) 53 (10) 12 (10) 1.3 (0.4, 4.6) 0.69
Years Qualified
<5 years 20 (3.0) 14 (2.5) 6 (5.2) Ref
5-10 years 86 (12.9) 75 (13.6) 11 (9.5) 0.8 (0.2, 2.9) 0.70
10-20 years 168 (25.2) 144 (26.2) 24 (20.7) 0.5 (0.2, 1.8) 0.33
>20 years 392 (58.9) 317 (57.6) 75 (64.7) 1.1 (0.4, 3.6) 0.83
Years working in general practice
<5 years 219 (32.8) 155 (28.2) 64 (54.2) Ref
5-10 years 87 (13.0) 63 (11.4) 24 (19.5) 0.9 (0.5, 1.9) 0.94
10-20 years 144 (21.6) 121 (22.0) 23 (19.5) 0.5 (0.3, 0.9) 0.03
>20 years 218 (32.6) 211 (38.4) 7 (5.9) 0.1 (0.0, 0.2) <0.01
Country of training
Overseas 235 (35.1) 227 (41.0) 8 (6.9) Ref
Australia 435 (64.9) 327 (59.0) 108 (93.1) 18.6 (7.0, 49.3) <0.01
Interest in sexual health
No 449 (67.6) 386 (70.7) 63 (53.4) Ref
Yes 215 (32.4) 160 (29.3) 55 (46.6) 1.7 (1.0, 2.8) 0.05
Questions related to chlamydia knowledge
Which age groups have the highest rates of chlamydia infection in women?
Incorrect 451 (69.8) 363 (68.4) 88 (76.5) Ref
Correct* 195 (30.2) 168 (31.6) 27 (23.5) 0.6 (0.3, 1.1) 0.08
Which age groups have the highest rates of chlamydia infection in men?
Incorrect 516 (83.2) 423 (83.1) 93 (83.8) Ref
Correct** 104 (16.8) 86 (16.9) 18 (16.2) 1.0 (0.5, 1.9) 0.94
Most chlamydia infections are asymptomatic in women
Disagree 67 (10.0) 53 (9.6) 14 (12.0) Ref
Agree^ 600 (90.0) 498 (90.4) 102 (88.0) 0.5 (0.2, 1.0) 0.06
Most chlamydia infections are asymptomatic in men
Disagree 157 (23.7) 136 (24.9) 21 (18.3) Ref
Agree^ 500 (75.5) 406 (74.2) 94 (81.7) 1.0 (0.6, 1.8) 0.98
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Close to 80% of PNs compared with about half of the
GPs, correctly identified that chlamydia testing should
be offered opportunistically in the following asymptomatic
clinical scenarios; a 23 year old female presenting for a
pap smear (84% vs 57%), a 24 year old pregnant female
(85% vs 45%) and a 22 year old Aboriginal or Torres Strait
Islander male with a sore throat (79% vs 34%). Similarly, a
higher proportion of PNs compared with GPs identified
that testing should be conducted in two other oppor-
tunistic scenarios which at the time were outside the
recommended age group; a 26 year old male presenting
for a truck license medical check (78% vs 30%) and a
33 year old female presenting for a pill prescription
(83% vs 55%). The difference between professions were
significant (p < 0.05 for all).
Nearly all PNs and GPs (around 97%) correctly identi-
fied that testing should be offered in young people pre-
senting with STI related symptoms (an 18 year old female
with abdominal pain and a 17 year old male with genital
warts) and when there is a risk of STIs (a 34 year old male
wanting a HIV test) (see Table 2).
Specimen collection
Although most PNs and GPs correctly identified the ap-
propriate specimens to be used for asymptomatic and
symptomatic patient presentations in women and asymp-
tomatic presentations in heterosexual men, PNs were less
likely to report correct responses for all three presenta-
tions (see Table 2). A much lower proportion of both GPs
and PNs could identify the appropriate specimens (urine)
for a heterosexual male with urethral discharge (26% vs
13%, p = 0.03) with three-quarters incorrectly indicating a
urethral swab should be collected, and the appropriate
specimen (urine, and rectal swab) for an asymptomatic
man who has sex with men (MSM) (21% vs 12%, p = 0.05)
with two-thirds failing to indicate a patient self-collected
rectal swab should be collected. The differences between
professions were all significant (see Table 2).
Retesting
PNs were more likely than GPs to correctly identify that
a follow up test is recommended after a negative result
(74% vs 33%, OR 4.9, 95% CI 2.9, 8.6) and it should be
conducted at one year (80% vs 51%, OR 3.3, 95% CI 1.1,
9.3), that a repeat test should be done after a positive
chlamydia result (93% vs 87%, OR 2.7, 95% CI 1.1, 6.4),
and the appropriate time frame is three months (66% vs
26%, OR 3.8, 95% CI 1.8, 8.11) (p < 0.05 for all).GP chlamydia treatment practices
When asked to choose from a possible list of antibiotics
that they usually prescribe for men or non- pregnant
women, the majority of GPs (91%) correctly indicated
that they usually prescribe azithromycin. In the case of
pregnant women with uncomplicated chlamydia infec-
tion, under half (41%) would usually prescribe the rec-
ommended antibiotic (azithromycin), with 22% choosing
erythromycin and 16% amoxicillin.
PN opinions and perceived barriers to testing
A high proportion of PNs agreed that they could conduct
chlamydia testing in general practice (90%), they should
have a greater role in chlamydia testing (79%) and require
additional training or skills to manage testing and treat-
ment of chlamydia (89%). The majority of the PNs wanted
more involvement in chlamydia testing in their practices
(79%) and to be involved in managing a recall/reminder
system for chlamydia testing (75%). Over half indicated
they would like involvement in discussing partner notifica-
tion with patients who test positive for chlamydia (61%).
The most commonly identified barriers to increasing
chlamydia testing were patients’ lack of chlamydia know-
ledge (69%) and time constraints during consultations
(53%), followed closely by the lack of a formal chlamydia
test recall/reminder system (46%) and lack of support for
partner notification (46%). A third (33%) identified patient
religion/ethnicity and a quarter (26%) lack of support for
PNs as barriers, with less than a quarter identifying diffi-
culty talking with clients about sexual health (21%) and
cost of testing to client (21%). A very low proportion of
nurses thought that the chance of patients getting a false
positive result (10%) and concerns about over servicing
(4%) were barriers to increasing chlamydia testing (see
Table 3).
Discussion
This survey identifies some important gaps in the chla-
mydia knowledge and self reported practices of GPs and
PNs which may contribute to low chlamydia testing
rates and suboptimal management of chlamydia in
young people attending Australian general practice
clinics. Knowledge of the age groups at greatest risk of
chlamydia, especially in men, was poor in both profes-
sions. PNs demonstrated greater knowledge and more cor-
rect testing and retesting practices than GPs, but were less
likely to collect the appropriate specimens for chlamydia
testing. In addition, most of the GPs indicated that they
were not prescribing the recommended antibiotic treat-
ment for pregnant women with chlamydia. The study also
demonstrated that although the majority of PNs were will-
ing to become more involved in chlamydia testing and just
over half in partner notification, they identified potential
barriers to increasing testing including time constraints,
Table 2 Chlamydia practice - testing scenarios and specimens
Questions relating to chlamydia practice Overall n (%) GP n (%) PN n (%) OR (95% CI) P value
Should chlamydia testing be offered to: 23 year old female, pap smear
No 259 (38.6) 240 (43.3) 19 (16.4) Ref
Yes* 411 (61.3) 314 (56.7) 97 (83.6) 3.3 (1.8, 6.0) <0.01
18 year old woman, lower abdominal pain
No 28 (4.2) 27 (4.9) 1 (0.9) Ref
Yes* 642 (95.8) 528 (95.1) 114 (99.1) 5.6 (.6, 50.8) 0.12
26 year old man, truck license medical examination
No* 466 (69.5) 432 (77.8) 34 (29.6) Ref
Yes 204 (30.5) 123 (22.2) 81 (70.4) 0.1 (0.1, 0.2) <0.01
24 year old woman, 16 weeks pregnant
No 322 (48.2) 304 (55.1) 18 (15.6) Ref
Yes* 345 (51.7) 248 (44.9) 97 (84.4) 7.3 (3.6, 14.6) <0.01
22 year Aboriginal man, sore throat
No 393 (58.6) 369 (66.5) 24 (20.8) Ref
Yes* 277 (41.3) 186 (33.5) 91 (79.1) 7.1 (3.9, 12.9) <0.01
33 year old woman in stable relationship, pill script
No* 523 (78.2) 459 (83.0) 64 (55.2) Ref
Yes 146 (21.8) 94 (17.0) 52 (44.8) 0.3 (0.2, 0.5) <0.01
17 year old man, genital warts
No 20 (3.0) 17 (3.1) 3 (2.6) Ref
Yes* 651 (97.0) 538 (96.9) 113 (97.4) 1.4 (.4, 5.4) 0.62
34 year old man, 2 female partners in 6 months, HIV test
No 16 (2.4) 13 (2.4) 3 (2.6) Ref
Yes* 652 (97.6) 540 (97.6) 112 (97.4) 1.0 (0.2, 5.4) 0.98
Which specimens can be used to test for chlamydia in the following patients:
Heterosexual female, no genital symptoms1
Incorrect 29 (4.4) 14 (2.6) 15 (13.3) Ref
Correct 631 (95.6) 533 (97.4) 98 (86.7) 0.15 (0.1, 0.4) <0.001
Heterosexual female, abnormal vaginal/cervical discharge2
Incorrect 44 (6.6) 19 (3.5) 25 (22.1) Ref
Correct 620 (93.4) 532 (96.5) 88 (77.9) 0.13 (0.1, 0.3) <0.01
Heterosexual male, no genital symptoms3
Incorrect 62 (9.5) 31 (5.7) 31 (27.7) Ref
Correct 592 (90.5) 511 (94.3) 81 (72.3) 0.14 (0.1, 0.3) <0.01
Heterosexual man, urethral discharge4
Incorrect 502 (76.4) 404 (74.3) 98 (86.7) Ref
Correct 155 (23.6) 140 (25.7) 15 (13.3) 0.45 (0.2, 0.9) 0.03
Man who has sex with men, no genital symptoms5
Incorrect 203 (81.2) 146 (78.9) 57 (87.7) Ref
Correct 47 (18.8) 39 (21.1) 8 (12.3) 0.28 (0.1, 1.0) 0.05
*Correct answer.
1Acceptable specimens - cervical or high vaginal or self collected vaginal swabs or urine 2Acceptable specimens - cervical or high vaginal or self collected vaginal
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PNs can conduct chlamydia testing in general practice 102 (89.5) 12 (4.4) 7 (6.1)
PNs should have a greater role in chlamydia testing 90 (78.9) 3 (2.6) 21 (18.4)
PNs require additional training/skills to manage chlamydia testing and
treatment
100 (88.5) 6 (5.3) 7 (6.2)
I would like to be more involved with chlamydia testing in my practice 88 (78.6) 3 (2.7) 21 (18.7)
I would like to be involved with managing a recall/reminder system for
chlamydia testing
84 (75) 7 (6.2) 21 (18.8)
I would like to be involved with discussing partner notification with patients
who test positive for chlamydia
68 (60.7) 17 (15.2) 27 (24.1)
Possible barriers to increasing chlamydia testing Yes n (%) No n (%) Not sure n (%)
Concerns about over servicing 5 (4.4) 81 (70.4) 29 (25.2)
Cost of testing to client 23 (20.5) 72 (64.3) 17 (15.2)
Time constraints 59 (52.7) 41 (36.6) 12 (10.7)
Difficulty talking with clients about sexual health 24 (21.4) 70 (62.5) 18 (16.1)
Lack of support for practice nurses 28 (25.5) 63 (57.3) 19 (17.2)
Chance of patients getting false positive 11 (9.8) 65 (58.1) 36 (32.1)
Patients lack of chlamydia knowledge 78 (69.1) 24 (21.2) 11 (9.7)
Religion/ethnicity of patient 37 (32.7) 51 (45.2) 25 (22.1)
Lack of formal chlamydia test recall/reminder system 52 (46.4) 42 (37.5) 18 (16.1)
Lack of support for partner notification 51 (46) 31 (27.9) 29 (26.1)
PN, practice nurse.
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systems to facilitate repeat testing.
The survey had a number of strengths. To our know-
ledge this is the first survey examining PN chlamydia
knowledge and practice specifically and comparing the
responses of PNs and GPs. Second, because of the direct
questionnaire administration method and reminders the
response rates were very high, comparable with the 85%
response rate achieved by Mulvey et al. [20] and a vast
improvement on more recent response rates achieved in
other postal chlamydia knowledge and practice surveys
in Australian general practice settings [17,19,21]. A
similar system of sending reminders to non-responders
was undertaken by Hocking et al. and achieved response
rates of 60% [18].
A number of limitations should also be noted. About a
quarter of clinicians did not return the questionnaire.
The characteristics of these non responders are not avail-
able but it is possible they were less interested in sexual
health and our study findings related to knowledge and
practices may be overestimated. The ability to detect
significant differences between professions was ham-
pered by the lower sample size of PNs. Also the PNs
who participated in the survey reflect nurses who were
selected by their clinics to be involved in chlamydia
testing if randomised to the intervention arm, whereas
the majority of GPs were recruited. Thus the PNs mayrepresent a more interested group of PNs, which may
account for high levels of knowledge compared to GPs.
The GPs are also unlikely to be representative of all
Australian GPs, with most from rural towns where
many overseas trained doctors are required to work for
ten years before receiving access to Medicare benefits
arrangements [28]. The result is an over- representation
(41%) of overseas trained GPs in the sample compared
with one-third in Australia GPs overall [29]. It should
be noted however, that there were no significant differ-
ences in knowledge or correct practices between GPs
trained overseas compared with those trained in Australia.
GPs reported they wouldn’t offer chlamydia testing
opportunistically in a range of clinical presentations, in-
cluding pap smears and pregnancy, which explains the
low testing rate currently seen in general practice [11],
and the low uptake of chlamydia testing in antenatal
screening [30]. Testing only those with symptoms or
reported risk will achieve a very low testing coverage,
with the baseline prevalence survey of patients attending
ACCEPt clinics finding only 5% presented for STI-related
reasons [31]. Previous Australian and UK research exam-
ining GPs’ chlamydia knowledge and practice also found
that GPs were less likely to offer testing during asymptom-
atic presentations, even those related to chlamydia testing,
such as pap smears [19,21,32-34]. Conversely, the partici-
pating PNs in our survey thought that testing should be
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narios presented, even in age groups outside of that
recommended guidelines current at the time of the
survey suggesting a greater commitment to opportunistic
testing. This may be because nurses view sexual health as
an integral part of holistic care and thus part of their
role. PNs may also feel more comfortable discussing
and offering chlamydia testing in unrelated consulta-
tions, compared with GPs, who may fear “offending” or
“insulting” patients [16,35,36]. A reduced awareness of
those age groups with the highest risk of chlamydia may
also lead to missed opportunities for testing in the target
age group and over testing in older age groups. It is very
important that PNs are aware of the target age groups for
chlamydia testing, as they are important providers of pap
smears in Australian general practice and since 2006 have
had the ability to undertake chlamydia testing at the time
of cervical screening. Past initiatives linking chlamydia
testing to pap smears have resulted in higher testing rates
in older, lower risk age groups [37], and lower rates in
younger women not eligible for cervical screening [38].
Inconsistencies in knowledge regarding recommended
specimen collection suggest that respondents’ may be
unfamiliar with guidelines for testing. Most identified
acceptable specimens for asymptomatic patients and
symptomatic female patients, but not for symptomatic
heterosexual males and MSM. This could reflect lack of
experience in STI testing for MSM due to the lower
populations of MSM in rural areas or lack of awareness
of patients’ sexuality due to not asking or gay men
themselves not disclosing [39]. Research examining the
comprehensiveness of STI testing in MSM shows that
anal (and throat) swabs are the least common specimen
collected [40,41].
By far, GPs had poorer knowledge about the need for
chlamydia retesting and the appropriate time frame. This
explains why in general practice only a quarter of young
people are currently re-testing at 3 months following a
positive chlamydia diagnosis and of those tested, only
7% are retesting in 12 months [42]. Recent data from
England’s National Chlamydia Screening Programme
(NCSP) revealed moderate annual repeat testing rates
with 18% (overall NCSP) to 26% (GUM clinics) of young
people re-tested within one year, and a higher propor-
tion of positive retests in those who tested positive at
baseline [10]. Lack of clinician awareness or inconsisten-
cies in the guidelines recommendations on the timing of
retesting may explain Australian GPs poor knowledge in
this area. RACGP guidelines advise repeat testing from
3-12 months following chlamydia infection, compared
with other STI management guidelines recommending
3 months [9,26]. However, within our sample, over half
of the GPs (63%) who identified the need for a repeat
test following chlamydia diagnosis thought that this testshould be performed before 12 weeks, with just under
half (44%) choosing between 1 to 5 weeks, a timeframe
in which retesting may result in a false positive result
due to the presence of non-viable chlamydial DNA [43].
GPs self reported treatment practices are also suggestive
of unfamiliarity with current guidelines. Whilst the major-
ity indicated that they would usually prescribe azithromy-
cin for men or non-pregnant women, under half chose
azithromycin for the treatment of chlamydia infection in
pregnant women. Almost the same proportion would use
amoxicillin or erythromycin, which despite being effective
in treating chlamydia infection, are associated with more
adverse gastro-intestinal side effects and poorer adherence
than azithromycin [44].
It is encouraging to note that not only do PNs in this
survey demonstrate good baseline chlamydia knowledge
but they are also willing to undertake a role in all aspects
of chlamydia management, including partner notification
and management of recall systems for chlamydia retesting,
whilst also identifying the need to undergo additional
training to do so. The perceived barriers to increasing
chlamydia testing were consistent with those previously
identified by Australian GPs in a study by Hocking et al.
[35] and GPs and PNs in the UK [15,16,34,36].
Conclusions
In conclusion, chlamydia infection and re-infection are
important health issues for young people. General
practice is ideally placed to implement a successful
chlamydia screening programme that may have the po-
tential, through increasing testing, to impact on the
burden of chlamydia in this population. Despite this,
testing rates in general practice are poor and as this
survey reveals, important gaps in chlamydia knowledge
and practice and barriers to testing exist amongst clini-
cians. To fully support clinicians in achieving increased
testing rates, these gaps and barriers must be ad-
dressed. The multifaceted ACCEPt intervention, which
is tailored to each participating clinic, is appropriately
designed and targeted to achieve this. Finally, PNs,
with their demonstrated levels of chlamydia knowledge
and willingness to offer testing opportunistically have the
potential to make a significant contribution to chlamydia
testing in general practice and therefore strategies to
increase their involvement must be explored.
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